The discussions focused on the latest progress indicators of the MoU's provisions and the outcomes of their joint work. Both parties also explored ways to bolster cooperation in supporting cancer treatment and updating therapeutic protocols for heart diseases. The partnership's scope in training, awareness, and prevention is also set to broaden, aligning with Egypt's Vision 2030.
El-Sobky emphasized the GAH's ambition to transform the
Aswan Oncology Center into an advanced regional research and treatment hub for
cancer. This initiative, he said, would be realized through collaboration with
international partners, including Novartis, to enhance the center's role in
delivering cutting-edge care and fostering scientific research in oncology. He
extended an official invitation to Novartis officials to visit the Aswan Medical
Center to explore avenues for practical cooperation.
Discussions also covered enhancing doctor training on the
latest scientific advancements in treating heart diseases and breast cancer.
This is part of the GAH's commitment to regularly update therapeutic protocols,
ensuring optimal patient care. El-Sobky highlighted the importance of
increasing the number of doctors benefiting from training programs with
Novartis to amplify the impact of professional development on healthcare
service delivery.
The meeting also touched on mechanisms for launching an
accredited e-training platform, a joint venture between the GAH and Novartis,
aimed at qualifying family doctors in managing non-communicable diseases such
as hypertension, diabetes, and chronic heart conditions.
Furthermore, both sides discussed developing innovative
solutions to boost health awareness, ensure continuous medical follow-up for
patients, and achieve a more efficient and sustainable healthcare experience.
Dr. El-Morr reiterated Novartis's commitment to expanding
cooperation, particularly in early detection, treatment of cancer patients,
heart diseases, and non-communicable diseases. She noted that each joint
initiative with the GAH yields concrete results, contributing to improving
patients' quality of life and supporting the overall healthcare system.
Attendees from Novartis Egypt included Dr. Rania Ashraf,
Head of External Affairs for Novartis Middle East and Africa, Dr. Amr Nasr,
Head of External Affairs for Novartis Egypt, and Dr. Abdulaziz Ahmed, Head of
Market Access.
Representing the General Authority for Healthcare were Dr. Hany Rashid, Vice Chairman of the Authority, Dr. Farid Moharram, Member of the Authority's Board of Directors and Dean of the Faculty of Commerce at Ain Shams University, Dr. Amir El-Telwany, Executive Director of the Authority, Dr. Ahmed Hammad, Advisor to the Chairman of the Authority for Health Policies and Systems and Director-General of the General Department of Strategic Management, Dr. Wael Omran, Advisor to the Chairman of the Authority for Supply Affairs and Director-General of the General Department of Administrative Affairs, Dr. Mahmoud El-Deeb, Assistant Executive Director for Planning and Health Mapping Affairs and Director-General of the Technical Office of the Chairman of the Authority, Dr. Heba Oweida, Director-General of the General Department of Research and Development; Dr. Radwa Imam, Deputy Director-General of the General Department of Primary Care for Population Health, Director of Family Medicine Centers, and Supervisor of the Initiatives and Health Awareness Unit, and Dr. Maha Saeed, Director of the Pharmacovigilance Unit.